title: An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer.
abstract: There were 80 patients with measurable metastatic or unresectable pancreatic cancer randomly assigned to treatment with either DHAD, VP-16, aclacinomycin, or spirogermanium. There were no complete or partial responses. Two deaths from leukopenia occurred in patients treated with DHAD. One patient receiving spirogermanium experienced a seizure. No other life-threatening toxicities occurred. Maximal toxicities were not significantly more frequent with any treatment group. Median survival was 10 weeks, and median time to progression was only 6 weeks, with no difference among these four therapies.
authors.affiliation: Genesee Hospital, University of Rochester Cancer Center, New York 14607.
authors.forename: R F
authors.initials: RF
authors.lastname: Asbury
authors.forename: A
authors.initials: A
authors.lastname: Cnaan
authors.forename: L
authors.initials: L
authors.lastname: Johnson
authors.forename: J
authors.initials: J
authors.lastname: Harris
authors.forename: S D
authors.initials: SD
authors.lastname: Zaentz
authors.forename: D G
authors.initials: DG
authors.lastname: Haller
mesh_terms: D015250:Aclarubicin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use; D015996:Survival Rate
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D013141:Spiro Compounds; C011157:aclacinomycins; C026818:spirogermanium; D005047:Etoposide; D015250:Aclarubicin; D008942:Mitoxantrone